Multiple roles of fucoxanthin and astaxanthin against Alzheimer's disease: Their pharmacological potential and therapeutic insights

[1]  A. Iraji,et al.  Design, synthesis, in silico and biological evaluations of novel polysubstituted pyrroles as selective acetylcholinesterase inhibitors against Alzheimer’s disease , 2022, Scientific Reports.

[2]  S. Tabrez,et al.  Nrf2/HO-1 Signaling Stimulation through Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) Provides Neuroprotection in Ethidium Bromide-Induced Experimental Model of Multiple Sclerosis , 2022, Genes.

[3]  F. Remião,et al.  Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform , 2022, Ageing Research Reviews.

[4]  S. Baboota,et al.  Pathogenic mechanisms and therapeutic promise of phytochemicals and nanocarriers based drug delivery against radiotherapy-induced neurotoxic manifestations , 2022, Drug delivery.

[5]  Md. Abdul Hannan,et al.  A Systematic Review on Marine Algae-Derived Fucoxanthin: An Update of Pharmacological Insights , 2022, Marine drugs.

[6]  T. Snell,et al.  Astaxanthin Bioactivity Is Determined by Stereoisomer Composition and Extraction Method , 2022, Nutrients.

[7]  Tao Zhang,et al.  Simultaneous Inhibitory Effects of All-Trans Astaxanthin on Acetylcholinesterase and Oxidative Stress , 2022, Marine drugs.

[8]  M. Bijak,et al.  Carotenoids from Marine Sources as a New Approach in Neuroplasticity Enhancement , 2022, International journal of molecular sciences.

[9]  E. Lima,et al.  Marine Organisms as Alkaloid Biosynthesizers of Potential Anti-Alzheimer Agents , 2022, Marine drugs.

[10]  V. Calabrese,et al.  Astaxanthin as a Modulator of Nrf2, NF-κB, and Their Crosstalk: Molecular Mechanisms and Possible Clinical Applications , 2022, Molecules.

[11]  A. Emwas,et al.  Natural Polysaccharides as Preventive and Therapeutic Horizon for Neurodegenerative Diseases , 2021, Pharmaceutics.

[12]  S. Sabiu,et al.  Astaxanthin-Mediated Bacterial Lethality: Evidence from Oxidative Stress Contribution and Molecular Dynamics Simulation , 2021, Oxidative medicine and cellular longevity.

[13]  M. Aschner,et al.  Anti-inflammatory action of astaxanthin and its use in the treatment of various diseases. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  Bojun Chen,et al.  PLGA-PEG Nanoparticles Facilitate In Vivo Anti-Alzheimer's Effects of Fucoxanthin, a Marine Carotenoid Derived from Edible Brown Algae. , 2021, Journal of agricultural and food chemistry.

[15]  K. Mohan,et al.  Dieckol: a brown algal phlorotannin with biological potential. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  R. Taliyan,et al.  Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB , 2021, Pharmaceutics.

[17]  Gun-Hee Kim,et al.  Mixture of Phlorotannin and Fucoidan from Ecklonia cava Prevents the Aβ-Induced Cognitive Decline with Mitochondrial and Cholinergic Activation , 2021, Marine drugs.

[18]  S. Singh,et al.  Therapeutic potential of astaxanthin and superoxide dismutase in Alzheimer's disease , 2021, Open Biology.

[19]  G. Zengin,et al.  Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors , 2021, Molecules.

[20]  Xiaojun Yan,et al.  Fucoxanthin has potential for therapeutic efficacy in neurodegenerative disorders by acting on multiple targets , 2021, Nutritional neuroscience.

[21]  M. Aschner,et al.  Nrf2 a molecular therapeutic target for Astaxanthin. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  G. Tseng,et al.  The effects of astaxanthin treatment on a rat model of Alzheimer’s disease , 2021, Brain Research Bulletin.

[23]  E. Mandelkow,et al.  A current view on Tau protein phosphorylation in Alzheimer's disease , 2021, Current Opinion in Neurobiology.

[24]  A. Iraji,et al.  Synthesis and biological activity of pyrimidines-containing hybrids: Focusing on pharmacological application , 2021, Journal of Molecular Structure.

[25]  E. Gallardo,et al.  Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches , 2021, Molecules.

[26]  O. Firuzi,et al.  Synthesis and bio-evaluation of new multifunctional methylindolinone-1,2,3-triazole hybrids as anti-Alzheimer's agents , 2021 .

[27]  Fei Li,et al.  Regulation of divalent metal ions to the aggregation and membrane damage of human islet amyloid polypeptide oligomers , 2021, RSC advances.

[28]  M. Farzaei,et al.  Marine Natural Products: Promising Candidates in the Modulation of Gut-Brain Axis towards Neuroprotection , 2021, Marine drugs.

[29]  H. Rhim,et al.  Prospects of Marine Sterols against Pathobiology of Alzheimer’s Disease: Pharmacological Insights and Technological Advances , 2021, Marine drugs.

[30]  F. Husain,et al.  Identification of butyrylcholinesterase and monoamine oxidase B targeted ligands and their putative application in Alzheimer's treatment: A computational strategy. , 2021, Current pharmaceutical design.

[31]  M. Kamel,et al.  Ameliorative effects of astaxanthin on brain tissues of alzheimer’s disease-like model: cross talk between neuronal-specific microRNA-124 and related pathways , 2021, Molecular and Cellular Biochemistry.

[32]  P. González,et al.  "Therapeutic uses of natural astaxanthin: An evidence-based review focused on human clinical trials". , 2021, Pharmacological research.

[33]  S. Smid,et al.  Phlorotannins: A review on biosynthesis, chemistry and bioactivity , 2021 .

[34]  C. Puglia,et al.  Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization , 2021, Nanomaterials.

[35]  M. Alajmi,et al.  Concatenation of molecular docking and molecular simulation of BACE-1, γ-secretase targeted ligands: in pursuit of Alzheimer’s treatment , 2021, Annals of medicine.

[36]  S. Bhatt,et al.  Role of reactive oxygen species in the progression of Alzheimer's disease. , 2020, Drug discovery today.

[37]  B. Chénais,et al.  Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy , 2020, International journal of molecular sciences.

[38]  O. Firuzi,et al.  Novel N‐benzylpiperidine derivatives of 5‐arylisoxazole‐3‐carboxamides as anti‐Alzheimer's agents , 2020, Archiv der Pharmazie.

[39]  A. Shikov,et al.  Pharmacokinetics of Marine-Derived Drugs , 2020, Marine drugs.

[40]  O. Firuzi,et al.  Design and synthesis of multi-target directed 1,2,3-triazole-dimethylaminoacryloyl-chromenone derivatives with potential use in Alzheimer's disease , 2020, BMC Chemistry.

[41]  M. Yang,et al.  Astaxanthin Improved the Cognitive Deficits in APP/PS1 Transgenic Mice Via Selective Activation of mTOR , 2020, Journal of Neuroimmune Pharmacology.

[42]  S. Sarker,et al.  Alzheimer’s disease: natural products as inhibitors of neuroinflammation , 2020, Inflammopharmacology.

[43]  F. Lu,et al.  Dual Effect of the Acidic Polysaccharose Ulvan on the Inhibition of Aβ Fibrillation and Disintegration of Mature Fibrils. , 2020, ACS applied materials & interfaces.

[44]  T. Spires-Jones,et al.  The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics , 2020, Acta Neuropathologica.

[45]  N. R. Jabir,et al.  In silico screening of glycogen synthase kinase-3β targeted ligands against acetylcholinesterase and its probable relevance to Alzheimer’s disease , 2020, Journal of biomolecular structure & dynamics.

[46]  Juanjuan Chen,et al.  Safety assessment of astaxanthin from Haematococcus pluvialis: Acute toxicity, genotoxicity, distribution and repeat-dose toxicity studies in gestation mice. , 2020, Regulatory toxicology and pharmacology : RTP.

[47]  A. Grumezescu,et al.  Marine Biocompounds for Neuroprotection—A Review , 2020, Marine drugs.

[48]  G. Perry,et al.  The Microbiota–Gut–Brain Axis–Heart Shunt Part II: Prosaic Foods and the Brain–Heart Connection in Alzheimer Disease , 2020, Microorganisms.

[49]  M. Moosavi‐Nasab,et al.  Encapsulation of fucoxanthin in binary matrices of porous starch and halloysite , 2020 .

[50]  Q. Pang,et al.  Fucoxanthin attenuates behavior deficits and neuroinflammatory response in 1-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine-induced Parkinson's disease in mice , 2020, Pharmacognosy Magazine.

[51]  Ravi Manjithaya,et al.  Dysfunctional Mitochondria and Mitophagy as Drivers of Alzheimer’s Disease Pathogenesis , 2019, Front. Aging Neurosci..

[52]  M. Hegde,et al.  Carotenoids as Novel Therapeutic Molecules Against Neurodegenerative Disorders: Chemistry and Molecular Docking Analysis , 2019, International journal of molecular sciences.

[53]  Wenmin Liu,et al.  Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease. , 2019, European journal of medicinal chemistry.

[54]  Z. You,et al.  Receptor-Mediated Delivery of Astaxanthin-Loaded Nanoparticles to Neurons: An Enhanced Potential for Subarachnoid Hemorrhage Treatment , 2019, Front. Neurosci..

[55]  Jie Liu,et al.  Targeting Autophagy for the Treatment of Alzheimer’s Disease: Challenges and Opportunities , 2019, Front. Mol. Neurosci..

[56]  D. Dickson,et al.  The neuropathological diagnosis of Alzheimer’s disease , 2019, Molecular Neurodegeneration.

[57]  Shengtao Xu,et al.  Multi-target design strategies for the improved treatment of Alzheimer's disease. , 2019, European journal of medicinal chemistry.

[58]  O. Firuzi,et al.  5,6-Diphenyl triazine-thio methyl triazole hybrid as a new Alzheimer’s disease modifying agents , 2019, Molecular Diversity.

[59]  M. Nguyen,et al.  Metal Ions in Alzheimer's Disease: A Key Role or Not? , 2019, Accounts of chemical research.

[60]  A. Lucacchini,et al.  Anti-Inflammatory Activities of Marine Algae in Neurodegenerative Diseases , 2019, International journal of molecular sciences.

[61]  B. Islam,et al.  The role of mitochondrial defects and oxidative stress in Alzheimer’s disease , 2019, Journal of drug targeting.

[62]  P. Baharvand,et al.  Astaxanthin induces apoptosis and increases activity of antioxidant enzymes in LS-180 cells , 2019, Artificial cells, nanomedicine, and biotechnology.

[63]  M. Akhtar,et al.  Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Aβ peptides in animal model of Alzheimer's disease. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[64]  O. Firuzi,et al.  Design and Synthesis of Selective Acetylcholinesterase Inhibitors: Arylisoxazole‐Phenylpiperazine Derivatives , 2019, Chemistry & biodiversity.

[65]  I. Musgrave,et al.  In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (Aβ1-42) toxicity and aggregation , 2019, Neurochemistry International.

[66]  Haiyan Zhang,et al.  Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease. , 2018, ACS chemical neuroscience.

[67]  Marie Kelly-Worden,et al.  Hypoglycemia, Hyperglycemia and Astaxanthin: An in Vitro Alzheimer’s Disease Model , 2019, Advances in Alzheimer's Disease.

[68]  N. R. Jabir,et al.  Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer’s disease , 2018, CNS neuroscience & therapeutics.

[69]  C. Pan,et al.  Fucoxanthin bioavailability from fucoxanthin-fortified milk: In vivo and in vitro study. , 2018, Food chemistry.

[70]  R. Miele,et al.  On the Neuroprotective Role of Astaxanthin: New Perspectives? , 2018, Marine drugs.

[71]  K. Ye,et al.  α‐Synuclein stimulation of monoamine oxidase‐B and legumain protease mediates the pathology of Parkinson's disease , 2018, The EMBO journal.

[72]  M. Mesulam,et al.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. , 2018, Brain : a journal of neurology.

[73]  T. Yanagita,et al.  Effects of Astaxanthin and Docosahexaenoic-Acid-Acylated Astaxanthin on Alzheimer's Disease in APP/PS1 Double-Transgenic Mice. , 2018, Journal of agricultural and food chemistry.

[74]  O. Firuzi,et al.  Synthesis and structure-activity relationship study of multi-target triazine derivatives as innovative candidates for treatment of Alzheimer's disease. , 2018, Bioorganic chemistry.

[75]  T. Asada,et al.  Effects of Composite Supplement Containing Astaxanthin and Sesamin on Cognitive Functions in People with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial , 2018, Journal of Alzheimer's disease : JAD.

[76]  Naoki Ito,et al.  Effects of Dietary Supplementation of Astaxanthin and Sesamin on Daily Fatigue: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study , 2018, Nutrients.

[77]  M. Hayashi,et al.  Effect of astaxanthin-rich extract derived from Paracoccus carotinifaciens on cognitive function in middle-aged and older individuals , 2018, Journal of clinical biochemistry and nutrition.

[78]  K. Ng,et al.  Tau Proteins and Tauopathies in Alzheimer’s Disease , 2018, Cellular and Molecular Neurobiology.

[79]  R. Thangavel,et al.  Mast Cell Activation in Brain Injury, Stress, and Post-traumatic Stress Disorder and Alzheimer's Disease Pathogenesis , 2017, Front. Neurosci..

[80]  O. Firuzi,et al.  Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease. , 2017, European journal of medicinal chemistry.

[81]  O. Firuzi,et al.  Discovery of imidazopyridines containing isoindoline-1,3-dione framework as a new class of BACE1 inhibitors: Design, synthesis and SAR analysis. , 2017, European journal of medicinal chemistry.

[82]  M. Kamal,et al.  Exploration of Various Proteins for the Treatment of Alzheimer's Disease. , 2017, Current drug metabolism.

[83]  W. Gerwick,et al.  Fucoxanthin, a Marine Carotenoid, Attenuates β-Amyloid Oligomer-Induced Neurotoxicity Possibly via Regulating the PI3K/Akt and the ERK Pathways in SH-SY5Y Cells , 2017, Oxidative medicine and cellular longevity.

[84]  Haopeng Sun,et al.  Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. , 2017, European journal of medicinal chemistry.

[85]  Qinwen Wang,et al.  Fucoxanthin Inhibits β-Amyloid Assembly and Attenuates β-Amyloid Oligomer-Induced Cognitive Impairments. , 2017, Journal of agricultural and food chemistry.

[86]  B. Islam,et al.  Management of Alzheimer's disease-An insight of the enzymatic and other novel potential targets. , 2017, International journal of biological macromolecules.

[87]  Jie Yu,et al.  Fucoxanthin prevents H2O2-induced neuronal apoptosis via concurrently activating the PI3-K/Akt cascade and inhibiting the ERK pathway , 2017, Food & nutrition research.

[88]  Xiang-yang Zou,et al.  Protective Effects of Fucoidan on Aβ25–35 and d-Gal-Induced Neurotoxicity in PC12 Cells and d-Gal-Induced Cognitive Dysfunction in Mice , 2017, Marine drugs.

[89]  Nobuko Hongo.  Daily Fatigue—reducing Effect of Astaxanthin―A Randomized, Placebo—controlled, Double—blind, Parallel—group Study― , 2017 .

[90]  S. Marder,et al.  Older Brains are Different: Brain-Behavior Studies and Their Clinical Utility. , 2017, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[91]  M. Kołaczkowski,et al.  Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation. , 2016, European journal of medicinal chemistry.

[92]  Jie Yu,et al.  Fucoxanthin, a Marine Carotenoid, Reverses Scopolamine-Induced Cognitive Impairments in Mice and Inhibits Acetylcholinesterase in Vitro , 2016, Marine drugs.

[93]  H. Chung,et al.  Kinetics and molecular docking studies of fucosterol and fucoxanthin, BACE1 inhibitors from brown algae Undaria pinnatifida and Ecklonia stolonifera. , 2016, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[94]  P. Francis,et al.  Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status , 2016, CNS Drugs.

[95]  R. Liu,et al.  Simultaneous Determination of Fucoxanthin and Its Deacetylated Metabolite Fucoxanthinol in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry , 2015, Marine drugs.

[96]  Z. Li,et al.  Neuroprotective effect of astaxanthin against glutamate-induced cytotoxicity in HT22 cells: Involvement of the Akt/GSK-3β pathway , 2015, Neuroscience.

[97]  O. Firuzi,et al.  N‐(2‐(Piperazin‐1‐yl)phenyl)arylamide Derivatives as β‐Secretase (BACE1) Inhibitors: Simple Synthesis by Ugi Four‐Component Reaction and Biological Evaluation , 2015, Archiv der Pharmazie.

[98]  N. D’Orazio,et al.  Anti-Obesity Activity of the Marine Carotenoid Fucoxanthin , 2015, Marine drugs.

[99]  C. Ritchie,et al.  Metal Ions in Alzheimer ’ s Disease Brain , 2015 .

[100]  V. Taneja,et al.  Toxic species in amyloid disorders: Oligomers or mature fibrils , 2015, Annals of Indian Academy of Neurology.

[101]  P. Andrade,et al.  Bioactive Compounds from Macroalgae in the New Millennium: Implications for Neurodegenerative Diseases , 2014, Marine drugs.

[102]  N. Brunton,et al.  Antioxidant activity and phenolic content of pressurised liquid and solid–liquid extracts from four Irish origin macroalgae , 2014 .

[103]  M. Lai,et al.  Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status , 2014, Drugs.

[104]  T. Wyss-Coray,et al.  Microglial dysfunction in brain aging and Alzheimer's disease. , 2014, Biochemical pharmacology.

[105]  R. Mayeux,et al.  Review - Part of the Special Issue: Alzheimer's Disease - Amyloid, Tau and Beyond Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers , 2014 .

[106]  Z. Leonenko,et al.  Effect of Metals on Kinetic Pathways of Amyloid-β Aggregation , 2014, Biomolecules.

[107]  Ampin Kuntiya,et al.  Anticholinesterase and Antioxidant Activities of Fucoxanthin Purified from the Microalga Phaeodactylum Tricornutum , 2013, Natural product communications.

[108]  Y. Jeon,et al.  Anti-diabetic effects of brown algae derived phlorotannins, marine polyphenols through diverse mechanisms. , 2013, Fitoterapia.

[109]  E. Ibáñez,et al.  Benefits of using algae as natural sources of functional ingredients. , 2013, Journal of the science of food and agriculture.

[110]  J. H. Viles,et al.  The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[111]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[112]  N. Thomas,et al.  Beneficial Effects of Marine Algal Compounds in Cosmeceuticals , 2013, Marine drugs.

[113]  S. Tsuji,et al.  Effects of astaxanthin-rich Haematococcus pluvialis extract on cognitive function: a randomised, double-blind, placebo-controlled study , 2012, Journal of clinical biochemistry and nutrition.

[114]  S. Mohamed,et al.  Seaweeds: A sustainable functional food for complementary and alternative therapy , 2012 .

[115]  M. Arfan Ikram,et al.  Variant of TREM 2 Associated with the Risk of Alzheimer ’ s Disease , 2012 .

[116]  B. Zlokovic.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[117]  C. Fillion,et al.  Effect of a commercially-available algal phlorotannins extract on digestive enzymes and carbohydrate absorption in vivo , 2011 .

[118]  T. Maoka,et al.  Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract , 2011, British Journal of Nutrition.

[119]  L. Cendron,et al.  Aluminum, copper, iron and zinc differentially alter amyloid-Aβ(1-42) aggregation and toxicity. , 2011, The international journal of biochemistry & cell biology.

[120]  H. Ross,et al.  Anti-proliferative and potential anti-diabetic effects of phenolic-rich extracts from edible marine algae , 2011 .

[121]  J. Brioni,et al.  Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer's Disease , 2011, Journal of Pharmacology and Experimental Therapeutics.

[122]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[123]  P. Mcgeer,et al.  Local neuroinflammation and the progression of Alzheimer’s disease , 2011, Journal of NeuroVirology.

[124]  L. Yonekura,et al.  Keto-carotenoids are the major metabolites of dietary lutein and fucoxanthin in mouse tissues. , 2010, The Journal of nutrition.

[125]  M. Valko,et al.  Metals, oxidative stress and neurodegenerative disorders , 2010, Molecular and Cellular Biochemistry.

[126]  N. Inamdar,et al.  Pharmacotherapeutic Approaches of Parkinson’s Disease , 2010 .

[127]  Peter Faller,et al.  Copper and Zinc Binding to Amyloid‐β: Coordination, Dynamics, Aggregation, Reactivity and Metal‐Ion Transfer , 2009, Chembiochem : a European journal of chemical biology.

[128]  Anders M. Dale,et al.  Regional Shape Abnormalities in Mild Cognitive Impairment and Alzheimer's Disease , 2009, NeuroImage.

[129]  Won‐Kyo Jung,et al.  Inhibitory effects and molecular mechanism of dieckol isolated from marine brown alga on COX-2 and iNOS in microglial cells. , 2009, Journal of agricultural and food chemistry.

[130]  Anqi Qiu,et al.  Regional shape abnormalities in mild cognitive impairment and Alzheimer's disease , 2009, NeuroImage.

[131]  T. Maoka,et al.  The distribution and accumulation of fucoxanthin and its metabolites after oral administration in mice , 2009, British Journal of Nutrition.

[132]  K. Browman,et al.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders , 2008, British journal of pharmacology.

[133]  N. Wood,et al.  Understanding the molecular causes of Parkinson's disease. , 2006, Trends in molecular medicine.

[134]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[135]  S. Tsai,et al.  Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer's disease , 1999, Neuroscience Letters.

[136]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[137]  Y. Ichimori,et al.  β-Amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity , 1996, Brain Research.